{"id":48589,"date":"2023-11-20T14:55:57","date_gmt":"2023-11-20T14:55:57","guid":{"rendered":"https:\/\/challengingthecrisis.com\/?p=48589"},"modified":"2023-11-20T16:37:29","modified_gmt":"2023-11-20T16:37:29","slug":"cardioactive","status":"publish","type":"post","link":"https:\/\/challengingthecrisis.com\/cs\/cardioactive\/","title":{"rendered":"CardioActive produkt recenze"},"content":{"rendered":"

\"\"Hypertenze je v Evrop\u011b v\u00fdznamn\u00fdm zdravotn\u00edm probl\u00e9mem. P\u0159ibli\u017en\u011b 22 % obyvatel Evropsk\u00e9 unie star\u0161\u00edch 15 let m\u011blo probl\u00e9my s vysok\u00fdm krevn\u00edm tlakem. Nejvy\u0161\u0161\u00ed m\u00edru hypertenze mezi zem\u011bmi EU hl\u00e1s\u00ed Chorvatsko (37 %), Loty\u0161sko (32 %) a Ma\u010farsko (32 %). Nejni\u017e\u0161\u00ed m\u00edru hypertenze vykazovalo Irsko (12 %), Lucembursko (Rumunsko), Nizozemsko a Lucembursko (po 16 %). <\/span><\/strong><\/p>\n

Hypertenzi hl\u00e1s\u00ed o n\u011bco \u010dast\u011bji \u017eeny ne\u017e mu\u017ei (23 % oproti 21 %). \u017deny ji \u010dast\u011bji uv\u00e1d\u011bj\u00ed (ve srovn\u00e1n\u00ed s mu\u017ei) a nejvy\u0161\u0161\u00ed m\u00edra hypertenze byla zji\u0161t\u011bna v Chorvatsku (38 %), Loty\u0161sku (37 %) a Ma\u010farsku (34 %).<\/span><\/strong><\/p>\n

Evropsk\u00e1 spole\u010dnost pro hypertenzi ozn\u00e1mila v roce 2023 nov\u00e1 komplexn\u00ed doporu\u010den\u00ed pro l\u00e9\u010dbu hypertenze. Tyto pokyny budou slou\u017eit jako n\u00e1stroj pro poskytovatele zdravotn\u00ed p\u00e9\u010de na cel\u00e9m sv\u011bt\u011b, kte\u0159\u00ed l\u00e9\u010d\u00ed hypertenzi. Arteri\u00e1ln\u00ed hypertenze, kterou trp\u00ed 1,28 miliardy dosp\u011bl\u00fdch na sv\u011bt\u011b, je hlavn\u00ed p\u0159\u00ed\u010dinou srde\u010dn\u00edch infarkt\u016f, mozkov\u00fdch p\u0159\u00edhod a selh\u00e1n\u00ed ledvin.<\/span><\/p>\n

Pokyny ESH maj\u00ed n\u011bkolik kl\u00ed\u010dov\u00fdch bod\u016f:<\/span><\/p>\n

Aktualizovan\u00e9 protokoly o m\u011b\u0159en\u00ed a monitorov\u00e1n\u00ed v\u010detn\u011b doporu\u010den\u00ed pro c\u00edlov\u00e9 hodnoty krevn\u00edho tlaku v ordinaci pro v\u011bt\u0161inu dosp\u011bl\u00fdch. (C\u00edlov\u00e9 rozmez\u00ed 140-120 mmHg, systolick\u00fd tlak; 80-70 mmHg, diastolick\u00fd tlak).<\/span><\/p>\n

Sou\u010d\u00e1st\u00ed doporu\u010den\u00ed je fyzick\u00e1 aktivita, zm\u011bna stravov\u00e1n\u00ed a zm\u011bna \u017eivotn\u00edho stylu.<\/span><\/p>\n

Nov\u00e9 a zjednodu\u0161en\u00e9 pokyny pro p\u0159edepisov\u00e1n\u00ed zahrnuj\u00ed zah\u00e1jen\u00ed l\u00e9\u010dby dvojkombinac\u00ed l\u00e9k\u016f, zvy\u0161ov\u00e1n\u00ed d\u00e1vek a\u017e na maxim\u00e1ln\u00ed tolerovanou \u00farove\u0148 a p\u0159\u00edpadn\u011b i na trojkombinaci. Rovn\u011b\u017e jsou uvedena doporu\u010den\u00ed pro pou\u017eit\u00ed v\u00edce l\u00e9k\u016f v jedn\u00e9 tablet\u011b.<\/span><\/p>\n

\r\n
\r\n <\/p>\n

\ud83d\udd25 <\/span>\u00a0CardioActive <\/span><\/strong>\u00a0<\/span>\ud83d\udd25<\/span><\/a>
\n\u2702 <\/span>CENA\u00a0-50%<\/span><\/strong> <\/span>\ud83d\uded2<\/span><\/a><\/p>\n

\r\n <\/div>\r\n <\/div>\n

Existuje \u0159ada r\u016fzn\u00fdch skupin l\u00e9k\u016f, kter\u00e9 lze pou\u017e\u00edt, v\u010detn\u011b blok\u00e1tor\u016f kalciov\u00fdch kan\u00e1l\u016f, jako jsou thiazidy, blok\u00e1tory receptor\u016f pro angiotenzin (RAS), a tak\u00e9 nov\u011bj\u0161\u00ed l\u00e9ky, jako jsou SGLT2 a nesteroidn\u00ed MRA.<\/span><\/p>\n

Novinky v l\u00e9\u010db\u011b hypertenze, v\u010detn\u011b definice doporu\u010den\u00e9 l\u00e9\u010dby hypertenze rezistentn\u00ed, stejn\u011b jako pou\u017eit\u00ed ren\u00e1ln\u00ed nervov\u00e9 denaturace.<\/span><\/p>\n

K dispozici jsou nov\u00e9 algoritmy l\u00e9\u010dby chronick\u00fdch stav\u016f, jako je srde\u010dn\u00ed selh\u00e1n\u00ed, chronick\u00e9 onemocn\u011bn\u00ed ledvin a sekund\u00e1rn\u00ed formy hypertenze.<\/span><\/p>\n

Roz\u0161\u00ed\u0159en\u00e1 doporu\u010den\u00ed pro screening a l\u00e9\u010dbu u r\u016fzn\u00fdch populac\u00ed pacient\u016f. Obsahuje specifick\u00e1 doporu\u010den\u00ed t\u00fdkaj\u00edc\u00ed se strategi\u00ed pro pokra\u010dov\u00e1n\u00ed v l\u00e9\u010db\u011b, jako je minimalizace klinick\u00e9 setrva\u010dnosti a nonadherence.<\/span><\/p>\n

Hled\u00e1te pomoc? Chcete sn\u00ed\u017eit hypertenzi? M\u016fj \u010dl\u00e1nek o p\u0159\u00edpravku Cardioactive obsahuje dal\u0161\u00ed informace o p\u0159\u00edpravku Cardioactive.<\/span><\/strong><\/p>\n

\"\"<\/p>\n

\u00da\u010dinky p\u0159\u00edpravku Cardioactive – opravdu funguje? Jak p\u016fsob\u00ed? Zku\u0161enosti pacient\u016f<\/h2>\n

Zaj\u00edmaj\u00ed v\u00e1s \u00fa\u010dinky p\u0159\u00edpravku Cardioactive? P\u0159\u00edrodn\u00ed p\u0159\u00edpravek je skv\u011bl\u00fdm zp\u016fsobem, jak podpo\u0159it regeneraci. M\u016f\u017ee ji tak\u00e9 pomoci udr\u017eet. Cardioactive je skv\u011bl\u00fdm p\u0159\u00edpravkem v boji proti hypertenzi. Bezpe\u010dn\u011b sni\u017euje krevn\u00ed nap\u011bt\u00ed. Nav\u00edc posiluje c\u00e9vy. Bylo prok\u00e1z\u00e1no, \u017ee Cardioactive je \u00fa\u010dinn\u00fdm prost\u0159edkem v boji proti vysok\u00e9mu krevn\u00edmu tlaku, a to bez ohledu na v\u00e1\u0161 v\u011bk.<\/span><\/p>\n

Zjist\u011bte v\u00edce o jeho vlastnostech<\/span><\/p>\n